CF Foundation President and CEO Robert J. Beall, Ph.D. testified today before the House of Representatives' Energy and Commerce Committee at a hearing entitled, “21st Century Cures: Incorporating the Patient Perspective.”
A comprehensive, updated resource to assist the cystic fibrosis community with infection prevention and control practices is now available online. “Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update” will also be published in the August print edition of Infection Control & Hospital Epidemiology, the official journal of the Society for Healthcare Epidemiology of America.
Teen volunteers from 27 states across the country gathered in Washington, D.C., on June 26 to advocate for friends and loved ones who have cystic fibrosis during the Cystic Fibrosis Foundation's sixth annual Teen Advocacy Day.
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
Comedian and longtime friend of the Cystic Fibrosis Foundation, Lewis Black, brought together some of the biggest names in the entertainment business for a variety show that benefited the Cystic Fibrosis Foundation on May 5.
More than 60 CF Foundation volunteers came together in Washington, D.C. to speak with their elected officials on behalf of friends and family members affected by the disease during March on the Hill, the Cystic Fibrosis Foundation's signature annual advocacy event.
A decade of strategic efforts to improve care has played a profound role in improving the quality and length of life for people with cystic fibrosis in the United States, according to a series of reports published in the April issue of BMJ Quality & Safety (formerly the British Medical Journal).